GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Acquired by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board lifted its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 5.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 166,142 shares of the company’s stock after purchasing an additional 9,200 shares during the quarter. Canada Pension Plan Investment Board’s holdings in GoodRx were worth $1,296,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. XTX Topco Ltd increased its stake in GoodRx by 42.4% during the second quarter. XTX Topco Ltd now owns 29,560 shares of the company’s stock worth $231,000 after acquiring an additional 8,801 shares during the last quarter. Plato Investment Management Ltd acquired a new stake in shares of GoodRx during the 2nd quarter worth about $43,000. Cornercap Investment Counsel Inc. increased its position in shares of GoodRx by 1.7% during the 2nd quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock worth $587,000 after purchasing an additional 1,266 shares during the last quarter. American Century Companies Inc. purchased a new stake in GoodRx in the 2nd quarter valued at about $18,183,000. Finally, ClariVest Asset Management LLC lifted its position in GoodRx by 27.4% in the second quarter. ClariVest Asset Management LLC now owns 195,722 shares of the company’s stock valued at $1,527,000 after buying an additional 42,097 shares during the last quarter. Hedge funds and other institutional investors own 63.77% of the company’s stock.

Insider Buying and Selling at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.17% of the stock is owned by insiders.

GoodRx Stock Up 2.2 %

GDRX stock opened at $6.85 on Friday. The company’s 50 day moving average price is $7.81 and its 200 day moving average price is $7.57. The firm has a market capitalization of $2.60 billion, a price-to-earnings ratio of -684.32, a PEG ratio of 3.38 and a beta of 1.38. GoodRx Holdings, Inc. has a fifty-two week low of $4.14 and a fifty-two week high of $9.26. The company has a debt-to-equity ratio of 0.96, a quick ratio of 7.32 and a current ratio of 7.32.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $200.60 million during the quarter, compared to analyst estimates of $200.47 million. GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. GoodRx’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.02 earnings per share. On average, equities research analysts anticipate that GoodRx Holdings, Inc. will post 0.14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on GDRX shares. Citigroup dropped their price target on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price for the company in a report on Friday, August 9th. UBS Group decreased their price target on GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research note on Friday, August 9th. Morgan Stanley lifted their price objective on GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a research note on Monday, June 10th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $10.00 target price on shares of GoodRx in a research note on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.36.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.